The inhibition of FOXM1 by genetic or pharmaceutical approach significantly impairs tumor growth of this cancer in vitro and in vivo[18,25,27,33], suggesting that targeting FOXM1 is an appealing and potential approach for anticancer therapeutics. Here, FOXM1 is linked to neoplasm.